PUBLICATIONS

Stockholm3 has been evaluated in several large clinical studies as well as in clinical practice. More than 75,000 men in Sweden and Norway have participated in clinical studies which include randomized and paired population-based screening studies, observational studies from routine clinical use and health economics studies. The scientific studies of Stockholm3 have been published in over 25 articles in leading scientific journals such as The Lancet Oncology and European Urology.

Comparison with risk calculator

Palsdottir et al. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort. European Urology Focus. 2022

Population-based diagnostic studies

Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015

Nordström et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI). The Lancet Oncology. 2021

Waldén et al. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science. 2022

Reality-based outcomes from clinical implementation

Bergman et al. Structured care for men who want to get tested for prostate cancer – findings from Capio Prostate Cancer Center. Läkartidningen. 2018

Eklund et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. European Urology Focus. 2016

Vinje et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. Scandinavian Journal of Primary Health Care. 2020

Stockholm3 as a reflex test

Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018

Health economic assessment

Hao et al. Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. European Urology. 2022

Karlsson et al. The cost effectiveness of prostate cancer screening using the Stockholm3 test. Plos One. 2021